Rinvoq vs Stelara
Side-by-side cost comparison based on Medicare Part D data
Rinvoq
Upadacitinib
Manufactured by AbbVie
Stelara
Ustekinumab
Manufactured by Janssen
Rinvoq costs 55% less per claim than Stelara ($3,498.00 vs $7,763.00).
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Rinvoq | Stelara |
|---|---|---|
| Avg Cost Per Claim | $3,498.00 | $7,763.00 |
| Total Medicare Spending | $2.3B | $5.6B |
| Total Beneficiaries | 92,000 | 114,000 |
| Total Claims | 648,000 | 720,000 |
| Annual Cost/Patient | $24,641.00 | $49,026.00 |
| Year-over-Year Change | +56.3% | +6.3% |
| Generic Available | No | Yes |
| Patent Expiration | Aug 16, 2033 | Jan 31, 2023 |
| Manufacturer | AbbVie | Janssen |
| Condition | Autoimmune Diseases | Autoimmune Diseases |
| Generic Name | Upadacitinib | Ustekinumab |
Rinvoq vs Stelara: What the Data Shows
Rinvoq (Upadacitinib) and Stelara (Ustekinumab) are both used to treat autoimmune diseases. Based on Medicare Part D data, Rinvoq costs $3,498.00 per claim, which is 55% less than Stelara at $7,763.00 per claim.
Medicare spent $2.3B on Rinvoq and $5.6B on Stelara. In terms of patient reach, Stelara serves more beneficiaries (114,000 vs 92,000).
Year-over-year spending changed +56.3% for Rinvoq and +6.3% for Stelara. Rinvoq saw significant spending growth, suggesting increased utilization or price increases.
Stelara has a generic available, while Rinvoq remains brand-only until its patent expires Aug 16, 2033.
Frequently Asked Questions
Rinvoq is cheaper at $3,498.00 per claim, compared to $7,763.00 for Stelara. That makes Rinvoq about 55% less expensive per claim based on Medicare Part D data.
Yes, both Rinvoq and Stelara are used to treat autoimmune diseases. Your doctor can help determine which medication is more appropriate for your specific situation.
Stelara has a generic version (Ustekinumab) available, which is typically much cheaper. Rinvoq is currently brand-only, with patent expiring Aug 16, 2033.
Medicare Part D spent $2.3B on Rinvoq covering 92,000 beneficiaries, and $5.6B on Stelara covering 114,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.